Alexander Mark Schobel, Chief Innovation/Tech Officer at Aquestive Therapeutics, Inc. (AQST), sold 55,895 shares at $5.19 ($288K) on 2024-03-08, disclosed to the SEC on 2024-03-12.
Scheduled sale ($288k) by Chief Innovation/Tech Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.19 | 25,000 | $130K | 45.0% |
| 2 | $5.19 | 25,000 | $130K | 45.0% |
| 3 | $4.88 | 5,895 | $29K | 10.0% |
| Total | $5.16 avg | 55,895 | $288K | 100% |
| Filing → |
| AQST | SELL | 2021-02-10 | $236K | — | Filing → |
| AQST | SELL | 2021-02-09 | $265K | — | Filing → |
| AQST | SELL | 2020-05-11 | $200K | — | Filing → |